Takeda(TKPHF)

TOKYO, JapanPharmaceutical1 H-1B visas (FY2023)

Focus: Takeda is a Japan-headquartered global pharmaceutical giant with 49,000 employees specializing in small molecules and enzymes across GI, rare diseases, neuroscience, and oncology. It operates as a diversified public company with meaningful commercial scale across multiple therapeutic areas.

GI/Gastroenterology Rare Diseases Neuroscience Oncology

Profile data last refreshed 38m ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

49,000

Open Jobs

5 recent layoff filings (12 mo) — 637 affected

3/25/2026 — Cambridge, MA · 247 affected · Layoff
3/25/2026 — Cambridge, MA · 247 affected · Layoff
1/15/2026 — Cambridge, MA · 3 affected · Layoff
+2 more

Source: state DOL filings via Big Local News

About Takeda

AI assessmentNot Hiring

No open roles listed right now. Follow Takeda to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthWatch

Pipeline

Early-stage

50 total

LOE Risk

3 imminent

ACTOPLUS MET XR

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

TRINTELLIX

Major Depressive Disorder, Generalized Anxiety Disorder

$390M (Part D)

Peak

Help build intelligence for Takeda

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified product portfolio across 4 major therapeutic areas with 10 peak/revenue-generating products generating $1.3B+ annually from top 8 marketed drugs
Substantial pipeline with 1,100+ active clinical trials across rare diseases, hemophilia, GI, and oncology offering breadth of research opportunities
Engineering and R&D are top hiring departments (58 and 36 open roles) indicating investment in innovation infrastructure and drug development capability

Watch Out For

Recent restructuring (600 US layoffs reported April 2026) and Cambridge facility closure signal cost-cutting pressure amid patent cliff exposure
$374M revenue at risk from MOTEGRITY (2028) and NINLARO (2029) LOE within 3 years with limited pipeline breakthroughs near approval

Generated by Claude from Takeda's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Flagship antidepressant driving 23% of revenue; patent protection extends to 2032 providing 6+ year runway.

NINLARO

Multiple Myeloma, Primary Amyloidosis

$312M (Part D)

Peak3.5yr

Leading oral proteasome inhibitor in hematology; loses patent protection in 2029 creating near-term revenue cliff risk.

VYVANSE

ADHD, Binge Eating Disorder, Major Depressive Disorder

$139M (Part D)

Peak

Multi-indication CNS stimulant with established market presence; patent status unclear but approaching maturity.

ENTYVIO

Ulcerative Colitis, Crohn's Disease, expanding to ICI-related colitis

$100M (Part D)

Growth

Biologic integrin antagonist with expanding indications including checkpoint inhibitor-related complications; longer exclusivity provides growth potential.

MOTEGRITY

Chronic Constipation, Opioid-Induced Constipation

$62M (Part D)

Peak2.2yr

GI serotonin-4 agonist losing patent in 2028; second major cliff event within 3-year window.

Pipeline & Clinical Trials

90Second IBD

IBD

N/A

Clinical Trials (1)

NCT0568613590Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients

N/A

Pen and Paper Digit Symbol Substitution Test

Major Depressive Episode

N/A

Freeze-dried live attenuated measles and rubella combined vaccine

Measles/Rubella

N/A

Clinical Trials (2)

NCT02151773Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination

N/A

NCT02158364Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination

A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insuff

Chronic Adrenal Insufficiency

N/A

Clinical Trials (1)

NCT01661387A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)

N/A

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

Angioedemas, Hereditary

N/A

Clinical Trials (1)

NCT04955964A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

N/A

Recombinant ADAMTS13

Thrombotic Thrombocytopenic Purpura (TTP)

N/A

Clinical Trials (2)

NCT06441578A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

N/A

NCT07429942A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program

A Study on Vonoprazan in the Real-world Clinical Practice in China

Esophagitis Peptic

N/A

Clinical Trials (1)

NCT04501627A Study on Vonoprazan in the Real-world Clinical Practice in China

N/A

The Myelin Disorders Biorepository Project

Leukodystrophy

N/A

Portable EEG Device

Healthy Volunteers

N/A

Clinical Trials (1)

NCT04445129Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants

N/A

Technochrom C1-INH Kit

Hereditary Angioedema (HAE)

N/A

Clinical Trials (1)

NCT07293364A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema

N/A

non-interventional retrospective epidemiological observational study

Secondary Immunodeficiencies (SID)

N/A

Clinical Trials (1)

NCT04172467Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients

N/A

No intervention

Hereditary Angioedema (HAE)

N/A

Clinical Trials (5)

NCT06405087A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Phase 3

NCT05442567A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

Hereditary Angioedema (HAE)

N/A

Clinical Trials (1)

NCT03845400A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

N/A

No Intervention

Carcinoma, Non-Small-Cell Lung

N/A

Clinical Trials (1)

NCT04887519A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

N/A

Effect of Stimulant Medication on Loss of Control Eating in Youth With Attention Deficit/Hyperactivi

Loss of Control Eating

N/A

Clinical Trials (1)

NCT05592119Effect of Stimulant Medication on Loss of Control Eating in Youth With Attention Deficit/Hyperactivity Disorder

N/A

LITMUS Imaging Study

NAFLD

N/A

No Intervention

Mucopolysaccharidosis (MPS)

N/A

Clinical Trials (1)

NCT05155488A Study to Improve the Awareness of Mucopolysaccharidosis Type II in Brazil

N/A

low-fat diet

Insulin Resistance

N/A

Clinical Trials (1)

NCT00457938Novel Therapies for Metabolic Complications of Lipodystrophies

N/A

assessment

Sanfilippo Syndrome Type A

N/A

Clinical Trials (5)

NCT01112982An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.

Phase 4

NCT00336219Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)

TAK-881

Primary Immunodeficiency Diseases (PIDD)

N/A

Clinical Trials (5)

NCT06747351A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Phase 3

NCT06076642A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

CUVITRU

Primary Immunodeficiency Diseases (PID)

N/A

Clinical Trials (4)

NCT03116347Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Phase 4

NCT05764993Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe In

Colitis, Ulcerative

N/A

Clinical Trials (1)

NCT03532932A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice

N/A

Diagnosis of SPAD using immunization with PPV23

Specific Antibody Deficiency

N/A

Clinical Trials (1)

NCT05664035SPAD in Adult Patients

N/A

No Intervention

Celiac Disease

N/A

Clinical Trials (1)

NCT05309330Virtual Celiac Symptoms Study in Adults and Teenagers

N/A

Vonoprazan

A History of Gastric or Duodenal Ulcers

N/A

Clinical Trials (5)

NCT03116841Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation

Phase 4

NCT02037477Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Natural History Study of Children With Metachromatic Leukodystrophy

Lipid Metabolism Disorders

N/A

Clinical Trials (1)

NCT01963650Natural History Study of Children With Metachromatic Leukodystrophy

N/A

TachoSil®

Lymph Node Resection

N/A

Clinical Trials (2)

NCT01500135Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

Phase 3

NCT01920958Use of Tachosil® for Lymph Sealing During Surgery

Virtual-reality

Hemophilia

N/A

Clinical Trials (1)

NCT05437211A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions

N/A

Esophageal dilation

Suspected Eosinophilic Esophagitis

N/A

Clinical Trials (1)

NCT00880906Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis

N/A

Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam

All Individuals Who Have Received at Least One Dose of TAK-003 (Qdenga) Dengue Vaccine

N/A

Clinical Trials (1)

NCT07501793Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam

N/A

Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease

Gastroesophageal Reflux

N/A

Clinical Trials (1)

NCT01167543Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease

N/A

Maralixibat

Alagille Syndrome (ALGS)

N/A

Clinical Trials (1)

NCT07293897A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)

N/A

Anti-TNF Therapy

Colitis, Ulcerative

N/A

Clinical Trials (1)

NCT03090139Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

N/A

Voglibose

Impaired Glucose Tolerance

N/A

Clinical Trials (1)

NCT01993927Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"

N/A

A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Tre

Von Willebrand Disease (VWD)

N/A

Clinical Trials (1)

NCT05265078A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi

N/A

Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Un

Stress Ulcer Prophylaxis

N/A

Clinical Trials (1)

NCT00919152Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Unit (ICU)

N/A

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants

Cytomegalovirus (CMV)

N/A

Clinical Trials (1)

NCT05576805A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada

N/A

Care bundle of active management

Cerebral Hemorrhage

N/A

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

Hemophilia

N/A

Clinical Trials (1)

NCT03818529ATHN 8: Previously Untreated Patients (PUPs) Matter Study

N/A

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT)

Cytomegalovirus (CMV)

N/A

Clinical Trials (1)

NCT05571137A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada

N/A

Confirmatory Testing

Acid Sphingomyelinase Deficiency

N/A

DXA scan + MRI

Bone Mineral Density

N/A

Clinical Trials (1)

NCT01460147Osteoporosis and MRI Study in Hemophilia

N/A

BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population

Plaque

N/A

Colonoscopy

N/A

Clinical Trials (2)

NCT00645801Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation

Phase 4

NCT00611442Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy

N/A

ATHN 9: Severe VWD Natural History Study

Von Willebrand Diseases

N/A

Clinical Trials (1)

NCT03853486ATHN 9: Severe VWD Natural History Study

N/A

Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age

Gastroesophageal Reflux

N/A

Clinical Trials (1)

NCT01048840Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age

N/A

Permeability measurement

Intestinal Diseases

N/A

Clinical Trials (1)

NCT02246647Biomarkers for Intestinal Permeability in Patients With Constipation

N/A

Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical

Mucopolysaccharidosis (MPS)

N/A

Clinical Trials (1)

NCT02095015Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)

N/A

TAK-577

Von Willebrand Disease (VWD)

N/A

Clinical Trials (1)

NCT06173024Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)

N/A

Inflammatory Bowel Disease in South Eastern Norway

Colitis, Ulcerative

N/A

Clinical Trials (1)

NCT02727959Inflammatory Bowel Disease in South Eastern Norway

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 94 approved products, 165 clinical trials

Top TAs: Oncology, Metabolic Diseases, Immunology

H-1B (2023): 1 approval

Publications: 58 in PubMed

Portfolio Health

Pre-Launch5 (5%)

Growth4 (4%)

Peak17 (18%)

LOE Approaching48 (51%)

Post-LOE20 (21%)

94 total products

Therapeutic Area Focus

Oncology

11 marketed302 pipeline

Metabolic Diseases

27 marketed167 pipeline

Immunology

6 marketed149 pipeline

Rare Diseases

3 marketed111 pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (5)

2026-03-25

247 employees affected— Cambridge, MA

source

2026-03-25

247 employees affected— Cambridge, MA

source

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis.

Journal of medical economics

2026

PMID:41823988

Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatment.

PIOGLITAZONE HYDROCHLORIDE

pioglitazone

Post-LOE

ORAL · TABLET

Peroxisome Proliferator-activated Receptor alpha Agonists

2018

NCT02528786Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study

Phase 1

NCT03763162Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

NCT05755035A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Phase 2/3

NCT04636502Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID)

N/A

NCT02388737Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis

Phase 3

13 marketed83 pipeline

Cardiovascular

10 marketed73 pipeline

Neurology

5 marketed76 pipeline

Nephrology

5 marketed45 pipeline

2026-01-15

3 employees affected— Cambridge, MA

source

2026-01-15

3 employees affected— Cambridge, MA

source

2025-10-01

137 employees affected— Cambridge, MA

source

Source: state DOL filings, aggregated via Big Local News

Takeda laid off 600 US staff and 250 Cambridge employees amid billion-dollar restructuring in April 2026, driven by leadership changes and strategic capital reallocation.

Recent layoff scale and leadership shakeup signal organizational instability; consolidation in commercial and manufacturing roles likely as cost-cutting priorities shift resources toward pipeline.

Journal of medical economics

2026

PMID:41811308

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Takeda(TKPHF)

About Takeda

Why Work Here

Key Products

Watch Out For

Products & Portfolio (32)

Key Products by Revenue

Other Products (8)

Pipeline & Clinical Trials

Recent News · Takeda(10)

Open Jobs (0)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (5)

Research Publications(10)